Integrity Is the Foundation
Equator Therapeutics
By Garrett Dempsey, Ph.D.
October 2025
When Jonah Sinick, Ph.D., co-founded Equator Therapeutics, he expected the scientific hurdles. After all, developing new therapies is never straightforward. What he didn’t anticipate was just how central team dynamics would be to building a biotech company—and how much his leadership philosophy would be shaped by it.
Equator runs lean, with just five core members. Jonah’s co-founder, Yuriy Kirichok, Ph.D., anchors the scientific foundation. Medicinal chemist Katherine Widdowson, Ph.D., brings decades of experience, while bench scientist Simon Vu, Ph.D., impressed the team by quickly mastering the company’s pipeline. A fourth scientist, who originally built that pipeline, now contributes part-time while pursuing an academic career. For Jonah, this tight-knit group isn’t a limitation. It’s intentional. “Getting people up to speed can be a big climb,” he explains. “It’s worth being careful.”
That cautious approach extends to Equator’s broader philosophy. Jonah insists on intellectual honesty and integrity as the company’s guiding values—qualities he admits aren’t always rewarded in biotech, where founders can feel pressure to oversell early data. “If you fundraise on bad data, you end up in a spiral,” he says. Instead, Equator takes the harder road, stress-testing results before pursuing capital. It’s slower, but Jonah believes it builds a stronger foundation.
The therapies Equator is developing may one day transform lives. But it’s the team—and the way they endure uncertainty together—that gives the company its true strength.
This emphasis on integrity carries into external partnerships. When selecting CROs, Jonah has learned that responsiveness and clarity matter just as much as scientific reputation. “Promptness of response is often predictive of how the relationship will go,” he notes. A partner who takes weeks to answer a question risks derailing progress, no matter their credentials.
Of course, the journey hasn’t been easy. Equator has weathered the uncertainty of grant delays and shifting government policies that directly affect how far dollars can stretch. Jonah acknowledges the emotional toll. “There’s a big contrast between the excitement of starting something new and the grind that follows when results take longer and resources run thin,” he says. Maintaining morale has required recalibrating expectations, giving space for recovery, and celebrating small wins while waiting for breakthrough moments.
What holds the team together, Jonah believes, is its size. With so few people, everyone is indispensable, and that sense of ownership keeps the mission tangible. He recalls Peter Thiel’s advice to “stay small as long as possible,” noting that beyond a certain headcount, redundancy creeps in and individuals lose their sense of purpose.
For Jonah, leading Equator is about more than advancing science. It’s about cultivating trust, resilience, and a culture where data and integrity come first. The therapies Equator is developing may one day transform lives. But it’s the team—and the way they endure uncertainty together—that gives the company its true strength.